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        It is now well established that HIV can 
escape the immune responses that could 
otherwise control the infection, includ-
ing both antibody and T cell responses. 
The latter has received much attention 
since it was fi  rst proposed in 1991 (  1  ), 
and selection of escape mutations in sev-
eral HIV epitopes targeted by CD8 
+   
T cells has been carefully documented 
(  2  –  5  ). Epitope escape usually occurs 
early in infection, as the rapidly repli-
cating virus displays almost every possi-
ble mutation enabling it to evade any 
suppressive force. Although such escape 
mutations often undermine immune con-
trol, many also have a fi  tness cost for the 
virus (  2, 3  ) so that escape is not always 
bad for the patient. 
  The fi  rst described and best-studied 
HIV CTL epitope comes from the p24 
gag protein and spans amino acids 263  –
  272 (KRWIILGLNK). This epitope is 
presented to CD8 
+   T cells by HLA B27 
(  2, 4  –  8  ). In patients with HLA B27, the 
CD8 
+   T cell response is dominated by 
T cells specifi  c for this epitope, proba-
bly because these T cells are function-
ally diverse, bind antigen with relatively 
high avidity, and proliferate well (  9  ). 
This response appears early in infection 
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as the initial peak viremia declines (  10  ), 
but unusually, virus escape does not 
occur until late in infection (  8  ), probably 
because the escape requires more than 
one compensating mutation. In this is-
sue, Lichterfeld et al. (p.   2813  ; refer-
ence  11  ) show that one of the mutations 
involved in this escape enhances HLA 
B27 binding to the inhibitory receptor 
immunoglobulin-like transcript (ILT) 
molecule 4 (also known as LIR2), 
which is expressed on monocytes and 
DCs (  11  ). 
  Mechanics of a mutation 
  Peptides that bind to HLA B27 almost 
always have an arginine (R) at the sec-
ond position, which fi  ts snugly into the 
B pocket of the peptide-binding groove 
of the HLA molecule. The arginine at 
position 264 in the HIV-1 gag 
263  –  272   
epitope is encoded by the amino acid co-
don AGA (or more rarely, AGG). Escape 
can occur when this arginine is mutated. 
The single mutations that have been re-
corded at this codon include AAA (ly-
sine), ACA (threonine), and GGA or 
AGG (glycine). Although peptides with 
these substitutions may bind suffi   ciently 
to HLA B27 in in vitro assays, they are 
not recognized by T cells when ex-
pressed within the cell as viral or trans-
fected sequences (  8  ). These mutations 
thus eff  ectively remove the epitope from 
the immune response. Given the high 
replication and mutation rates of HIV-1, 
one might expect the virus to escape 
rapidly and completely from the early 
T cells that recognize this epitope. Escape 
from this epitope, however, typi  cally 
occurs only after several years, hap-
pening in at least 50% of HLA B27 
patients who are studied for several 
years (  3  ,   11  ,   12  , and unpublished data). 
According to the Los Alamos HIV se-
quence database, these mutations are very 
rare in the general population of HIV-
infected individuals, 95% of whom do 
not have HLA B27. 
  A possible explanation for the late 
escape was provided by Kelleher et al. 
(  7  ), who showed that the critical argi-
nine-to-lysine change at position 264 
(R264K) only occurred when there 
had been a pre  vious change of leucine-
to-methionine at position six in the 
epitope (L268M). Unlike the arginine 
at position 2, the side chain at position 6 
is not involved in HLA B27 binding 
but rather faces and interacts with the 
T cell receptor (  Fig. 1  ).   More recently, 
Schneidewind et al. (  4  ) showed that 
there is nearly always a third amino acid 
change that accompanies the R264K 
and L268M mutations: an alanine-to-
serine change at position 173 (A173S). 
This amino acid lies outside the epit-
ope, but the three mu  tated amino acids 
cluster in the three-dimensional struc-
ture of p24, suggesting that they might 
compensate for each other. The R264K 
mutation imparts a fi  tness cost on the 
virus, as elegantly shown by Goulder 
et al. (  2  ), who found that the virus 
rapidly mutated this sequence back to 
wild-type in HLA B27 
  −    babies that had 
been infected by B27 
+   mothers carry-
ing the mutated virus. This was directly 
tested in vitro by Schneidewind et al., 
who showed that an infectivity fi  t-
ness cost for the R264K mutation was 
compensated for by the A173S muta-
tion (  4  ). This requirement for a triple 
mutation must be much rarer than a 
single mutation, and probably accounts 
for the delayed escape from this T 
cell response. 2786 HIV TRIPLE ESCAPE | McMichael
  Complexity of HIV escape 
  These observations imply a novel escape 
mechanism involving the inhibitory 
ILT4 receptor. This is the fi  rst demon-
stration that mutation in an HIV-1 CTL 
epitope can contribute to virus escape 
by infl  uencing the interaction between 
HLA class I and a molecule other than 
the T cell receptor, although it is known 
that diff  erent epitope peptides (none yet 
known to escape) can infl  uence the in-
teraction between HLA molecules and 
other inhibitory receptors, such as the 
KIR family (  12  ). 
  This is an important story for under-
standing HIV infection. The virus must 
be under considerable immune pressure 
to select this complex mosaic of muta-
tions (Table I). Yet ultimately the virus 
evades immune control with the triple 
mutation and the virus load rises (  8  ). 
Because this requires such a long period 
of time, other factors such as the loss 
of CD4 T cells must also contribute to 
the progression to AIDS. However, 
patients with B27 do progress to dis-
ease more slowly than the average HIV-
infected individual, possibly because 
the B27-restricted T cells concentrate 
wild-type peptide with HLA B27. ILT4 
is present on monocytes and DCs, and 
contains a cytoplasmic ITIM motif that 
delivers an inhibitory signal to the cell. 
Thus, the mutant peptide  –  B27 complex 
could impair the function of monocytes 
and DCs. One might expect this to have 
a negative eff  ect on T cell function. The 
authors show, however, that after the 
L268M mutation occurs, a vigorous new 
primary T cell response develops against 
the new epitope. This fact is diffi   cult to 
square with impaired DC function, but 
the authors provide a potential explana-
tion. They show that ILT4 expression 
on monocytes and DCs is low in early 
HIV infection and increases as the infec-
tion progresses. They argue that if the 
L268M mutation arises early in the in-
fection, the DCs can still prime new T cell 
responses, but as the infection progresses 
and ILT4 expression increases, other new 
T cell responses may be impaired by the 
ILT4-mediated inhibition of DCs. This 
could give the mutant virus a longer-term 
advantage. It will thus be interesting to 
compare the breadth of T cell responses 
late in infection in B27 
+   patients who do 
or do not have this epitope mutation.   
  Mutation disarms DCs 
  In this issue, Lichterfeld et al. (  11  ) report 
a longitudinal study, which shows that 
the L268M change occurs early in infec-
tion, suggesting that it is the fi  rst in the 
sequence of changes that leads to escape, 
and that the mutation becomes fi  xed 
(Table I). Fixation implies that the mu-
tation confers some advantage for the vi-
rus in the presence of the T cell response. 
The leucine at this position is likely to 
interact with the T cell receptor (  Fig. 1  ), 
and the initial T cell response tends to 
be specifi  c for the L-containing epitope. 
This response then drives selection of 
the M-containing mutant, which in turn 
stimulates a new cross-reactive T cell 
response (  11  ). Any advantage of the M-
containing epitope would therefore 
seem to be transient, but the fact that this 
mutation persists suggests that it confers 
some other, as yet unknown, advantage 
to the virus. 
  Lichterfeld et al. now give an intrigu-
ing insight into what this advantage 
might be. They show that complexes of 
the L268M mutant peptide bound to 
HLA B27 bind to ILT4 with three times 
higher affi   nity than do complexes of the 
  Figure 1.     Diagrammatic representation of the side chains of the HIV-1 gag peptide KRWIILGLNK bound to HLA-B27, according to 
the structure determined by Stewart-Jones et al. (reference   13  ). The     -1 helix is shown as a light blue dotted line. The floor of the peptide-
binding groove below the peptide and      2 helix are not depicted. Only the side chains of leucine 268 (L6) and asparagine 271 (N9) are exposed to 
the T cell receptor.     
  Table I.     Triple bypass 
Mutation Timing Effect Reference
L268M First Enhanced ILT4 binding (11)
R264K (T/G) Second/third Abrogation of peptide binding to B27 (7)
S173A Second/third Compensating effect (4) JEM VOL. 204, November 26, 2007  2787
COMMENTARY
on a conserved part of the virus that 
requires this complicated and slow eva-
sion process. 
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